A fully automated micro-CT deep learning approach for precision preclinical investigation of lung fibrosis progression and response to therapy

被引:8
作者
Buccardi, Martina [1 ,7 ]
Ferrini, Erica [2 ]
Pennati, Francesca [3 ]
Vincenzi, Elena [4 ,5 ]
Ledda, Roberta Eufrasia [6 ]
Grandi, Andrea [7 ]
Buseghin, Davide [6 ]
Villetti, Gino [7 ]
Sverzellati, Nicola [6 ]
Aliverti, Andrea [3 ]
Stellari, Franco Fabio [7 ]
机构
[1] Univ Parma, Dept Math Phys & Comp Sci, Parma, Italy
[2] Univ Parma, Dept Vet Sci, Parma, Italy
[3] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy
[4] Univ Genoa, Dept Comp Sci Bioengn Robot & Syst Engn, Genoa, Italy
[5] Camelot Biomed Syst SRL, Via Ponte Reale 2-20, I-16124 Genoa, Italy
[6] Univ Parma, Dept Med & Surg, Parma, Italy
[7] Chiesi Farmaceut SPA, Expt Pharmacol & Translat Sci Dept, I-43122 Parma, Italy
关键词
Bleomycin model; Lung fibrosis; Deep learning; Drug discovery; Micro-computed tomography; PULMONARY-FIBROSIS; NINTEDANIB; MODELS;
D O I
10.1186/s12931-023-02432-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Micro-computed tomography (mu CT)-based imaging plays a key role in monitoring disease progression and response to candidate drugs in various animal models of human disease, but manual image processing is still highly time-consuming and prone to operator bias. Focusing on an established mouse model of bleomycin (BLM)-induced lung fibrosis we document, here, the ability of a fully automated deep-learning (DL)-based model to improve and speed-up lung segmentation and the precise measurement of morphological and functional biomarkers in both the whole lung and in individual lobes. mu CT-DL whose results were overall highly consistent with those of more conventional, especially histological, analyses, allowed to cut down by approximately 45-fold the time required to analyze the entire dataset and to longitudinally follow fibrosis evolution and response to the human-use-approved drug Nintedanib, using both inspiratory and expiratory mu CT. Particularly significant advantages of this mu CT-DL approach, are: (i) its reduced experimental variability, due to the fact that each animal acts as its own control and the measured, operator bias-free biomarkers can be quantitatively compared across experiments; (ii) its ability to monitor longitudinally the spatial distribution of fibrotic lesions, thus eliminating potential confounding effects associated with the more severe fibrosis observed in the apical region of the left lung and the compensatory effects taking place in the right lung; (iii) the animal sparing afforded by its non-invasive nature and high reliability; and (iv) the fact that it can be integrated into different drug discovery pipelines with a substantial increase in both the speed and robustness of the evaluation of new candidate drugs. The mu CT-DL approach thus lends itself as a powerful new tool for the precision preclinical monitoring of BLM-induced lung fibrosis and other disease models as well. Its ease of operation and use of standard imaging instrumentation make it easily transferable to other laboratories and to other experimental settings, including clinical diagnostic applications.
引用
收藏
页数:16
相关论文
共 37 条
  • [1] Nintedanib for treating progressive fibrosing interstitial lung diseases
    Adler, Amanda, I
    Guo, Yelan
    Thiam, Aminata
    Elliott, Nicole
    Patel, Sanjeev
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (12) : E116 - E117
  • [2] Automated lung segmentation for thoracic CT: Impact on computer-aided diagnosis
    Armato, SG
    Sensakovic, WF
    [J]. ACADEMIC RADIOLOGY, 2004, 11 (09) : 1011 - 1021
  • [3] Lung imaging: how to get better look inside the lung
    Ball, Lorenzo
    Vercesi, Veronica
    Costantino, Federico
    Chandrapatham, Karthikka
    Pelosi, Paolo
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (14)
  • [4] Bayne K, 1996, Physiologist, V39, P208
  • [5] Automatization and improvement of μCT analysis for murine lung disease models using a deep learning approach
    Birk, Gerald
    Kaestle, Marc
    Tilp, Cornelia
    Stierstorfer, Birgit
    Klee, Stephan
    [J]. RESPIRATORY RESEARCH, 2020, 21 (01)
  • [6] The normal and fibrotic mouse lung classified by spatial proteomic analysis
    Ciccimarra, Roberta
    Bolognesi, Maddalena M.
    Zoboli, Matteo
    Cattoretti, Giorgio
    Stellari, Franco F.
    Ravanetti, Francesca
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
    du Sert, Nathalie Percie
    Hurst, Viki
    Ahluwalia, Amrita
    Alam, Sabina
    Avey, Marc T.
    Baker, Monya
    Browne, William J.
    Clark, Alejandra
    Cuthill, Innes C.
    Dirnagl, Ulrich
    Emerson, Michael
    Garner, Paul
    Holgate, Stephen T.
    Howells, David W.
    Karp, Natasha A.
    Lazic, Stanley E.
    Lidster, Katie
    MacCallum, Catriona J.
    Macleod, Malcolm
    Pearl, Esther J.
    Petersen, Ole H.
    Rawle, Frances
    Reynolds, Penny
    Rooney, Kieron
    Sena, Emily S.
    Silberberg, Shai D.
    Steckler, Thomas
    Wurbel, Hanno
    [J]. EXPERIMENTAL PHYSIOLOGY, 2020, 105 (09) : 1459 - 1466
  • [8] Administration of Bleomycin via the Oropharyngeal Aspiration Route Leads to Sustained Lung Fibrosis in Mice and Rats as Quantified by UTE-MRI and Histology
    Egger, Christine
    Cannet, Catherine
    Gerard, Christelle
    Jarman, Elizabeth
    Jarai, Gabor
    Feige, Agnes
    Suply, Thomas
    Micard, Arthur
    Dunbar, Andrew
    Tigani, Bruno
    Beckmann, Nicolau
    [J]. PLOS ONE, 2013, 8 (05):
  • [9] Ferrini E., 2020, FRONT VET SCI, V8, P7
  • [10] A new anesthesia protocol enabling longitudinal lung-function measurements in neonatal rabbits by micro-CT
    Ferrini, Erica
    Leo, Ludovica
    Corsi, Luisa
    Catozzi, Chiara
    Salomone, Fabrizio
    Ragionieri, Luisa
    Pennati, Francesca
    Stellari, Franco Fabio
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2021, 321 (06) : L1206 - L1214